Royal Bank of Canada’s Minerva Neurosciences NERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1K | Sell |
92
-2,148
| -96% | -$12.3K | ﹤0.01% | 6914 |
|
|
2025
Q4 | $9K | Sell |
2,240
-190
| -8% | -$705 | ﹤0.01% | 6474 |
|
|
2025
Q3 | $5K | Buy |
2,430
+2,378
| +4,573% | +$4.86K | ﹤0.01% | 6707 |
|
|
2025
Q2 | $0 | Sell |
52
-100
| -66% | -$163 | ﹤0.01% | 7231 |
|
|
2025
Q1 | $0 | Sell |
152
-1,393
| -90% | -$2.75K | ﹤0.01% | 7095 |
|
|
2024
Q4 | $3K | Buy |
+1,545
| New | +$3.65K | ﹤0.01% | 6655 |
|
|
2024
Q3 | – | Sell |
-1,829
| Closed | -$6K | – | 7228 |
|
|
2024
Q2 | $6K | Buy |
1,829
+1,280
| +233% | +$3.47K | ﹤0.01% | 6492 |
|
|
2024
Q1 | $1K | Buy |
549
+55
| +11% | +$338 | ﹤0.01% | 6827 |
|
|
2023
Q4 | $3K | Sell |
494
-831
| -63% | -$4.75K | ﹤0.01% | 6738 |
|
|
2023
Q3 | $9K | Buy |
1,325
+1,107
| +508% | +$9.91K | ﹤0.01% | 6461 |
|
|
2023
Q2 | $2K | Buy |
218
+42
| +24% | +$222 | ﹤0.01% | 6891 |
|
|
2023
Q1 | $0 | Buy |
+176
| New | +$364 | ﹤0.01% | 7338 |
|
|
2022
Q4 | – | Sell |
-1,181
| Closed | -$11K | – | 7545 |
|
|
2022
Q3 | $11K | Buy |
+1,181
| New | +$7K | ﹤0.01% | 6388 |
|
|
2021
Q3 | – | Sell |
-1,126
| Closed | -$21K | – | 7784 |
|
|
2021
Q2 | $21K | Buy |
1,126
+701
| +165% | +$15.1K | ﹤0.01% | 6541 |
|
|
2021
Q1 | $10K | Buy |
425
+159
| +60% | +$3.97K | ﹤0.01% | 6810 |
|
|
2020
Q4 | $5K | Buy |
266
+258
| +3,225% | +$6.5K | ﹤0.01% | 6638 |
|
|
2020
Q3 | $0 | Sell |
8
-30
| -79% | -$811 | ﹤0.01% | 6825 |
|
|
2020
Q2 | $1K | Buy |
38
+22
| +138% | +$1.29K | ﹤0.01% | 6457 |
|
|
2020
Q1 | $1K | Sell |
16
-239
| -94% | -$14.4K | ﹤0.01% | 6466 |
|
|
2019
Q4 | $15K | Buy |
+255
| New | +$11.2K | ﹤0.01% | 5986 |
|
|
2018
Q4 | – | Sell |
-75
| Closed | -$7K | – | 6990 |
|
|
2018
Q3 | $7K | Buy |
75
+58
| +341% | +$4.36K | ﹤0.01% | 6116 |
|
|
2018
Q2 | $1K | Buy |
+17
| New | +$1.03K | ﹤0.01% | 6372 |
|
|
2018
Q1 | – | Sell |
-10
| Closed | – | – | 6641 |
|
|
2017
Q4 | $0 | Sell |
10
-275
| -96% | -$13.6K | ﹤0.01% | 6762 |
|
|
2017
Q3 | $17K | Buy |
285
+270
| +1,800% | +$15.5K | ﹤0.01% | 6032 |
|
|
2017
Q2 | $1K | Sell |
15
-83
| -85% | -$5.37K | ﹤0.01% | 6416 |
|
|
2017
Q1 | $6K | Buy |
98
+95
| +3,167% | +$7.38K | ﹤0.01% | 6151 |
|
|
2016
Q4 | $0 | Buy |
+3
| New | +$306 | ﹤0.01% | 6722 |
|
Other funds holding NERV
VC
LGM
FCM
FCMV
VCM
ABG
SSC
Royal Bank of Canada's NERV Position: Q1 2026 in Review
Royal Bank of Canada reduced its Minerva Neurosciences (NERV) stake by 96% in Q1 2026, selling an estimated $12.3K and leaving 92 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #6914.
Royal Bank of Canada first reported a position in NERV in Q4 2016 and has held it in 27 quarters since. The position peaked at $21K in Q2 2021. 47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.
- Royal Bank of Canada held 92 shares of Minerva Neurosciences worth $1K as of Q1 2026.
- Royal Bank of Canada sold 2,148 Minerva Neurosciences shares in Q1 2026, an estimated $12.3K.
- Minerva Neurosciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6914 holding.
- Royal Bank of Canada first reported a position in Minerva Neurosciences in Q4 2016 and has held it in 27 quarters since.
- Royal Bank of Canada's Minerva Neurosciences position peaked at $21K in Q2 2021.
- 47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.